Prosecution Insights
Last updated: April 19, 2026

TransThera Sciences (Nanjing), Inc.

3 pending office actions

Portfolio Summary

3
Total Pending OAs
2
Final Rejections
1
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
18552878 COMBINED USE OF MULTIKINASE INHIBITOR MAYHEW, BRADLEY SCOTT 1621 Non-Final OA Sep 27, 2023
17791680 NOVEL USE OF MULTIKINASE INHIBITOR ENGLISH, CONNOR KENNEDY 1625 Final Rejection Jul 08, 2022
17268309 NOVEL QUINOLINE DERIVATIVE INHIBITOR BRAUN, MADELINE E 1624 Final Rejection Feb 12, 2021

Managing TransThera Sciences (Nanjing), Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month